Recent Updates
Recently added Catalysts
RGNX Positive Sentiment Score: 65/100

REGENXBIO to Participate in Upcoming Investor Conferences

Thursday, August 28, 2025 2 min read
Key Takeaway: REGENXBIO Inc. has announced its participation in several upcoming investor conferences including the Wells Fargo Healthcare Conference and the Morgan Stanley Global Healthcare Conference. The conferences will include various presentations and fireside chats, providing REGENXBIO an opportunity to engage with investors. Live webcasts of selected talks will be available, alongside archived replays post-event. This outreach reflects the company's ongoing strategy to connect with stakeholders and promote their advancements in gene therapy.

Market Sentiment Analysis

POSITIVE FACTORS

  • REGENXBIO is actively participating in several prestigious investor conferences.
  • The company showcases its commitment to engaging with the investment community.
  • Live webcasts of the presentations enhance accessibility for investors.

Full Press Release Details

ROCKVILLE, Md., Aug. 28, 2025 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced it will participate in the following investor conferences:
2025 Wells Fargo Healthcare Conference
1x1 Investor Meetings: Thursday, September 4
Location: Boston, MA
Morgan Stanley 23rd Annual Global Healthcare Conference
Fireside Chat: Monday, September 8, 2025 at 11:30 a.m. ET
Location: New York, NY
Baird 2025 Global Healthcare Conference
Fireside Chat: Tuesday, September 9, 2025 at 8:30 a.m. ET
Location: New York, NY
H.C. Wainwright 27th Annual Global Investment Conference
Fireside Chat: Tuesday, September 9, 2025 at 2:30 p.m. ET
Location: New York, NY
Live webcasts of select fireside chats can be accessed in the Investors section of REGENXBIO's website at www.regenxbio.com. An archived replay of the webcast will be available for approximately 30 days following the presentation.
ABOUT REGENXBIO Inc.
REGENXBIO is a biotechnology company on a mission to improve lives through the curative potential of gene therapy. Since its founding in 2009, REGENXBIO has pioneered the field of AAV gene therapy. REGENXBIO is advancing a late-stage pipeline of one-time treatments for rare and retinal diseases, including RGX-202 for the treatment of Duchenne; clemidsogene lanparvovec (RGX-121) for the treatment of MPS II and RGX-111 for the treatment of MPS I, both in partnership with Nippon Shinyaku; and surabgene lomparvovec (ABBV-RGX-314) for the treatment of wet AMD and diabetic retinopathy, in collaboration with AbbVie. Thousands of patients have been treated with REGENXBIO's AAV platform, including those receiving Novartis' ZOLGENSMA®. REGENXBIO's investigational gene therapies have the potential to change the way healthcare is delivered for millions of people. For more information, please visit WWW.REGENXBIO.COM.
Corporate Communications
George E. MacDougall
SOURCE REGENXBIO Inc.

21 %

more press release views with

Frequently Asked Questions

What conferences will REGENXBIO participate in September 2025?

REGENXBIO will attend the Wells Fargo, Morgan Stanley, Baird, and H.C. Wainwright conferences.

Where can I access webcasts of REGENXBIO's conferences?

Live webcasts of select fireside chats are available on REGENXBIO's Investors webpage.

What is REGENXBIO's mission?

REGENXBIO aims to improve lives through the curative potential of gene therapy.

What conditions are REGENXBIO’s therapies targeting?

Their therapies target rare and retinal diseases, including Duchenne and MPS I and II.

When was REGENXBIO founded?

REGENXBIO was founded in 2009 and has pioneered AAV gene therapy.

Tags: RGNX Viatris Investor Conferences Healthcare REGENXBIO investor conferences gene therapy healthcare
Last updated: Aug 28, 2025